Mary “Nora” Disis, MD, on Reevaluating the Potential of CAR-T Approaches in Ovarian Cancer
The director of University of Washington Medicine’s Cancer Vaccine institute discussed the importance of continuing to develop new CAR-T approaches in the ovarian cancer field despite initial setbacks.
“CAR T-cell products in the ovarian cancer space have been tested and haven't seemed to be that effective. They were done with first-generation technologies and 1 of the major problems was that they really didn't persist in the body, and so they really didn't have much of an antitumor effect. I think with strategies such as this that are engineering agents to help those CART-cell products persist we'll start seeing clinical efficacy with these products in ovarian cancer.”
Several clinical trials have evaluated various chimeric antigen receptor T-cell (CAR-T) therapies to treat patients with ovarian cancer. Because these initial efforts did not meet much success, some researchers and institutions have been hesitant to continuetrying new CAR-T approaches in this space, despite the great unmet need that remains for patients with advanced stage platinum-resistant ovarian cancer.
In an interview with CGTLive™’s sister publication OncLive®, Mary “Nora” Disis, MD, director of University of Washington Medicine’s Cancer Vaccine institute, discussed need to continue exploring CAR-T approaches in ovarian cancer and explained the potential that these advanced therapies have in treating solid tumors when certain obstacles are addressed. Disis coauthored a study entitled “Phase 1/1b study of PRGN-3005 autologous UltraCAR-T cells manufactured overnight for infusion next day to advanced stage platinum resistant ovarian cancer patients," which was presented at
REFERENCE
1. Liao JB, Stanton SE, Chakiath M, et al. Phase 1/1b study of PRGN-3005 autologous UltraCAR-T cells manufactured overnight for infusion next day to advanced stage platinum resistant ovarian cancer patients. Presented at: the American Society of Clinical Oncology (ASCO) 2023 Annual Meeting, held June 2-6, in Chicago, Illinois. Abstract #5590
Newsletter
Stay at the forefront of cutting-edge science with CGT—your direct line to expert insights, breakthrough data, and real-time coverage of the latest advancements in cell and gene therapy.
Related Articles
- Using Targeted Locus Amplification to Analyze Genetically Modified Cells
September 18th 2025
- Around the Helix: Cell and Gene Therapy Company Updates – September 17, 2025
September 17th 2025